Please check your internet connection and try again.
# IV Dexamethasone
## Overview
Dexamethasone is a potent, long-acting synthetic glucocorticoid with minimal mineralocorticoid activity. It provides intense anti-inflammatory and immunosuppressive effects.
## Primary Indications
* Cerebral edema (associated with neoplasms or neurosurgery)
* Bacterial meningitis (adjunctive therapy)
* Acute systemic allergic reactions/anaphylaxis
* Croup (pediatrics)
* Chemotherapy-induced nausea and vomiting (CINV) prevention
* Acute exacerbations of COPD or asthma
* COVID-19 (for patients requiring supplemental oxygen)
## Adult Dosing
* **Cerebral Edema:** Initial 10 mg IV, followed by 4 mg IV every 6 hours.
* **COVID-19:** 6 mg IV daily for up to 10 days.
* **Bacterial Meningitis:** 10 mg IV every 6 hours for 4 days; initiate with or before the first antibiotic dose.
* **CINV:** 10–20 mg IV as a single dose prior to chemotherapy.
* **Acute Allergic Reaction:** 4–20 mg IV once.
## Pediatric Dosing
* **Croup:** 0.6 mg/kg (max 10 mg) IV/IM as a single dose.
* **Bacterial Meningitis:** 0.15 mg/kg IV every 6 hours for 4 days.
* **Cerebral Edema:** Loading dose 1–2 mg/kg IV, followed by 1–1.5 mg/kg/day divided every 4–6 hours (max dose depends on clinical protocol).
* **Anti-emetic:** 0.1–0.5 mg/kg (max 10–20 mg) IV as a single dose.
## Dose Adjustments
* **Hepatic Impairment:** Clearance may be decreased; monitor for increased sensitivity to corticosteroid effects.
* **Renal Impairment:** No specific adjustment required.
## Contraindications
* Systemic fungal infections.
* Known hypersensitivity to dexamethasone or components of the formulation.
* Avoid live or attenuated vaccines during high-dose therapy.
## Adverse Effects
* **Metabolic:** Hyperglycemia, fluid retention, hypokalemia.
* **Psychiatric:** Insomnia, agitation, mood swings, psychosis.
* **Gastrointestinal:** Increased risk of peptic ulceration or GI bleeding.
* **Infections:** Increased susceptibility to secondary bacterial or fungal infections.
* **Long-term:** Osteoporosis, HPA axis suppression, myopathy.
## Key Drug Interactions
* **CYP3A4 Inducers:** (e.g., phenytoin, phenobarbital, rifampin) may decrease dexamethasone efficacy.
* **NSAIDs/Warfarin:** Increased risk of gastrointestinal ulceration and bleeding.
* **Diabetes Medications:** Dexamethasone significantly increases blood glucose; requires titration of insulin/hypoglycemic agents.
* **Live Vaccines:** Reduced efficacy and increased risk of disseminated infection.
## Monitoring
* Serum glucose (frequent checks in diabetic patients).
* Electrolytes (potassium).
* Blood pressure.
* Signs of infection or GI bleeding.
* Neuro status/Level of consciousness (if treating cerebral edema).
## Clinical Pearls
* **Administration:** May be given slow IV push (usually over 1–5 minutes) or diluted in D5W/NS for infusion.
* **HPA Suppression:** If used for more than a few days, consider a slow taper to avoid acute adrenal insufficiency.
* **Local Protocols:** Dosing for cerebral edema and prophylactic protocols often vary by institution; always consult local neurocritical care or oncology guidelines.
* **COVID-19:** Clinical efficacy is restricted to patients requiring supplemental oxygen/ventilation; it may be harmful in patients not requiring oxygen.
***
**Educational Disclaimer:** This information is for educational purposes only. Prescribing practices and clinical protocols change frequently. Always verify the most current prescribing information, institutional guidelines, and drug compatibility via official databases (e.g., Lexicomp, Epocrates, or hospital pharmacy resources) before clinical administration.
